سعر اكستاندي Xtandi‏ 40 مجم 112 كبسول 2026

Xtandi 40 mg capsules containing enzalutamide, an androgen receptor inhibitor for prostate cancer, by Astellas (distributed by Multipharma), Egypt; pack of 112 capsules.

• Most common adverse reactions (>=10%) include musculoskeletal pain, fatigue, hot flush, constipation, decreased appetite, diarrhoea, hypertension, haemorrhage, fall, fracture and headache.International label, same product · DailyMed (U.S. National Library of Medicine)

• None (the US label lists no contraindications).International label, same product · DailyMed (U.S. National Library of Medicine)

• Seizure occurred in 0.6% of patients; permanently discontinue in patients who develop a seizure.International label, same product · DailyMed (U.S. National Library of Medicine)
• Posterior reversible encephalopathy syndrome (PRES) and hypersensitivity: discontinue the drug.International label, same product · DailyMed (U.S. National Library of Medicine)
• Ischaemic heart disease: optimise management of cardiovascular risk factors; falls and fractures: evaluate fracture and fall risk.International label, same product · DailyMed (U.S. National Library of Medicine)

• Strong CYP2C8 inhibitors (e.g. gemfibrozil)Avoid; if unavoidable, reduce the XTANDI dosage.DailyMed (U.S. National Library of Medicine)
• Strong CYP3A4 inducersAvoid; if unavoidable, increase the XTANDI dosage.DailyMed (U.S. National Library of Medicine)
• Sensitive CYP3A4, CYP2C9 or CYP2C19 substratesAvoid coadministration with substrates for which a small decrease in concentration may cause therapeutic failure.DailyMed (U.S. National Library of Medicine)

• Not established in females; based on animal studies and mechanism, can cause fetal harm and loss of pregnancy.International label, same product · DailyMed (U.S. National Library of Medicine)
• No data on presence in human milk; enzalutamide and/or metabolites were present in milk of lactating rats.International label, same product · DailyMed (U.S. National Library of Medicine)

• Enzalutamide: Competitively inhibits androgen binding to androgen receptors, androgen receptor nuclear translocation and its interaction with DNA (US XTANDI label).